lebrikizumab
Sponsor LLY · listed as LLY
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
lebrikizumab is a clinical-stage drug asset sponsored by LLY, listed as LLY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Apr 25, 2027 (day precision, medium confidence), tied to trial NCT06526182. The asset is in Phase 3 and currently active not recruiting, studied in Dermatitis, Atopic. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-04-25
As disclosedApr 25, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06526182
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAlmirall, S.A.
Listed asLLY
Condition(s)Dermatitis, Atopic; Eczema
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More LLY catalysts